Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study

Objectives: Subcutaneous administration of pertuzumab and trastuzumab offers a faster alternative to intravenous infusion for patients with HER2-positive breast cancer. However, real-world data on its impact on costs and capacity remain limited. Therefore, this study aimed to compare healthcare reso...

Полное описание

Библиографические подробности

Главные авторы:	Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen, Frederick W. Thielen
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-12-01
Серии:	Breast
Предметы:	HER2-Positive breast cancer Pertuzumab and trastuzumab Subcutaneous administration Intravenous administration Healthcare resource utilization Cost analysis
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S0960977625005909
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!